SOAT1 and diffuse large B-cell lymphoma: The promising results of Ruxolitinib in patients with myelofibrosis and the emerging relevance of the JAK-STAT pathway in DLBCL pathogenesis, has led to an ongoing clinical trial in patients with relapsed DLBCL and T-cell lymphoma (Clinical Trials.gov Identifier: NCT01431209).